ArticleFrontiers in endocrinology2026
Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acromegaly is a rare, chronic disease caused by excessive growth hormone (GH) production due to pituitary adenoma. The disease severely impacts patients' health-related quality of life and mortality while imposing a substantial economic burden. Resistance to first-line medical treatment necessitates effective second-line therapies, including pasireotide long-acting release (PAS LAR) and pegvisomant (PEG). Objective: To evaluate the cost-effectiveness of PAS LAR versus PEG (monotherapy or combined with FGSRLs) and versus FGSRLs alone, as second-line medical treatments for adults with acromegaly who are not adequately controlled on FGSRLs, from the perspective of the Brazilian Unified Health System (SUS). Methods: A hybrid decision-tree and Markov model were developed to evaluate lifetime health and economic outcomes of assessed drugs. To inform the model, health outcomes data were sourced from clinical trials, real-world evidence, systematic reviews, and meta-analyses. Costs were extracted from the official Brazilian tariffs database. Comparators included the FGSRLs, lanreotide (LAN) and octreotide (OCT), and PEG, as monotherapy and in combination with FGSRLs. Deterministic and probabilistic sensitivity analysis were performed to assess the impact of uncertainty on results. The incremental cost-effectiveness ratio (ICER) was the primary analysis outcome. Results: PAS LAR was dominant versus PEG monotherapy and in combination with LAN, generating similar health benefits (an additional 0.17 and 0.10 QALYs, respectively) and lower therapy costs (savings of -R$538,945 [-US$100,675] and -R$782,542 [-US$146,179]). In the comparison with PEG combined with OCT, PAS LAR was less costly (-R$979,624 [-US$182,994]) and marginally less effective (-0.04 QALYs). Compared to FGSRLs, PAS LAR demonstrated improved health outcomes (QALYs) and increased cost. The ICERs were R$161,411 (US$30,152)/QALY and R$168,538 (US$31,483)/QALY versus OCT and LAN, respectively. Scenario analyses confirmed robustness across variations in key model inputs that have the highest impact on cost-effectiveness results. Conclusions: The findings showed that in the Brazilian SUS context, PAS LAR is cost-effective compared to PEG monotherapy and PEG + LAN, and cost-saving versus PEG + OCT. Compared to FGSRLs, PAS LAR provided better outcomes with higher costs. With limited options for second-line medical treatment in Brazil, the reimbursement of PAS LAR in acromegaly can be considered a cost-effective strategy for acromegaly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.